Edition:
United States

BioCryst Pharmaceuticals Inc (BCRX.OQ)

BCRX.OQ on NASDAQ Stock Exchange Global Select Market

4.90USD
23 Apr 2018
Change (% chg)

$-0.01 (-0.20%)
Prev Close
$4.91
Open
$4.95
Day's High
$4.95
Day's Low
$4.80
Volume
102,698
Avg. Vol
298,362
52-wk High
$7.39
52-wk Low
$3.95

Latest Key Developments (Source: Significant Developments)

Biocryst Pharmaceuticals And Idera Pharmaceuticals Reschedule Meetings To Vote On Proposed Merger
Tuesday, 10 Apr 2018 07:30am EDT 

April 10 (Reuters) - Idera Pharmaceuticals Inc - New Clinical Data On Idera's Imo ::BIOCRYST PHARMACEUTICALS AND IDERA PHARMACEUTICALS RESCHEDULE MEETINGS TO VOTE ON PROPOSED MERGER.BIOCRYST AND IDERA SPECIAL MEETINGS TO BE HELD ON JULY 10, 2018.NEW CLINICAL DATA ON IDERA'S IMO-2125 PROGRAM WILL BE AVAILABLE PRIOR TO VOTE.IDERA BOARD UNANIMOUSLY RECOMMENDS THAT IDERA STOCKHOLDERS VOTE "FOR" PROPOSED MERGER AT IDERA SPECIAL MEETING.  Full Article

RA Capital Management Opposes BioCryst Pharmaceuticals' Proposed Merger With Idera Pharmaceuticals
Monday, 2 Apr 2018 08:13am EDT 

April 2 (Reuters) - Idera Pharmaceuticals Inc ::RA CAPITAL MANAGEMENT OPPOSES BIOCRYST PHARMACEUTICALS' PROPOSED MERGER WITH IDERA PHARMACEUTICALS.‍RA CAPITAL MANAGEMENT SAYS HAS BENEFICIAL OWNERSHIP OF ABOUT 7.1 PERCENT OF BIOCRYST PHARMACEUTICALS' COMMON STOCK​.RA CAPITAL SAYS HAS "SERIOUS CONCERNS" ABOUT BIOCRYST PHARMACEUTICALS' PROPOSED DEAL WITH IDERA AND ITS "DILUTIVE IMPACT" ON BIOCRYST SHAREHOLDERS ‍​.  Full Article

Biocryst Pharmaceuticals Files Definitive Proxy Statement Related To Pending Merger With Idera Pharmaceuticals
Monday, 2 Apr 2018 08:00am EDT 

April 2 (Reuters) - Biocryst Pharmaceuticals Inc ::BIOCRYST PHARMACEUTICALS FILES DEFINITIVE PROXY STATEMENT IN CONNECTION WITH PENDING MERGER WITH IDERA PHARMACEUTICALS.‍BIOCRYST SPECIAL MEETING OF STOCKHOLDERS SCHEDULED FOR MAY 9, 2018​.‍RECOMMEND THAT ALL CO'S STOCKHOLDERS VOTE "FOR" MERGER PROPOSAL WITH IDERA PHARMA​.‍RECOMMEND STOCKHOLDERS VOTE "FOR" BIOCRYST PROPOSALS SET FORTH IN PROXY STATEMENT, INCLUDING "FOR" MERGER PROPOSAL​.  Full Article

Biocryst Announces Initiation Of The Phase 3 Apex-2 Trial Of BCX7353 In Patients With Hereditary Angioedema
Thursday, 15 Mar 2018 06:00am EDT 

March 15 (Reuters) - Biocryst Pharmaceuticals Inc ::BIOCRYST ANNOUNCES INITIATION OF THE PHASE 3 APEX-2 TRIAL OF BCX7353 IN PATIENTS WITH HEREDITARY ANGIOEDEMA.BIOCRYST PHARMACEUTICALS INC SEES REPORTING TOP-LINE RESULTS FROM APEX-2 PHASE 3 TRIAL IN FIRST HALF OF 2019.  Full Article

Biocryst Reports Q4 Loss Per Share of $0.20
Tuesday, 27 Feb 2018 08:30am EST 

Feb 27 (Reuters) - Biocryst Pharmaceuticals Inc ::BIOCRYST REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.20.Q4 REVENUE $3.9 MILLION VERSUS $9.0 MILLION.CASH, CASH EQUIVALENTS & INVESTMENTS TOTALED $159.0 MILLION AT DEC 31, 2017, REFLECTS INCREASE FROM $65.1 MILLION AT DEC 31, 2016.EXPECTS ITS 2018 NET OPERATING CASH USE TO BE IN RANGE OF $67 TO $90 MILLION.SEES 2018 OPERATING EXPENSES TO BE IN RANGE OF $85 TO $110 MILLION.  Full Article

Great Point Partners Opposes Biocryst Pharma Proposed Merger With Idera Pharma
Friday, 16 Feb 2018 01:20pm EST 

Feb 16 (Reuters) - Great Point Partners LLC::GREAT POINT PARTNERS LLC OPPOSES THE BIOCRYST PHARMACEUTICAL PROPOSED MERGER WITH IDERA PHARMACEUTICALS, INC..‍GREAT POINT PARTNERS, LLC SAYS BENEFICIALLY OWNING ABOUT 7.5 MILLION SHARES OF COMMON STOCK OF BIOCRYST PHARMACEUTICALS​.GREAT POINT PARTNERS SAYS BELIEVE BIOCRYST PHARMA'S SHARES ARE "UNDERVALUED".GREAT POINT PARTNERS SAYS BELIEVE IT IS "INCUMBENT" UPON BIOCRYST PHARMACEUTICAL BOARD TO EXPLORE ALTERNATIVE STRATEGIES.  Full Article

BioCryst Pharma files for mixed shelf of up to $200 million‍​
Wednesday, 8 Nov 2017 04:45pm EST 

Nov 8 (Reuters) - BioCryst Pharmaceuticals Inc :Files for mixed shelf of up to $200 million - SEC filing‍​.  Full Article

BioCryst Pharmaceuticals reports Q3 loss per share of $0.18
Tuesday, 7 Nov 2017 06:00am EST 

Nov 7 (Reuters) - BioCryst Pharmaceuticals Inc ::Reports third quarter 2017 financial results.Q3 loss per share $0.18.Q3 revenue $8.8 million versus $7.8 million.Q3 earnings per share view $-0.19 -- Thomson Reuters I/B/E/S.Q3 revenue view $4.6 million -- Thomson Reuters I/B/E/S.Expect to start single required phase 3 efficacy and long-term safety trials for BCX7353 in Q1 2018 ​.‍U.S. Orphan Drug Designation for BCX7353 received from FDA​.  Full Article

Biocryst’s Rapivab receives FDA approval for a pediatric indication
Thursday, 21 Sep 2017 06:00am EDT 

Sept 21 (Reuters) - Biocryst Pharmaceuticals Inc :Biocryst’s Rapivab (peramivir injection) receives FDA approval for a pediatric indication.Biocryst Pharmaceuticals Inc - ‍FDA has approved a supplemental new drug application for Rapivab​.  Full Article

BioCryst Pharmaceuticals announces underwritten public offering​
Monday, 11 Sep 2017 04:01pm EDT 

Sept 12 (Reuters) - BioCryst Pharmaceuticals Inc :BioCryst Pharmaceuticals Inc - ‍offering to sell $80 million of its common stock in an underwritten public offering​.Biocryst - ‍proceeds to be used for funding global launch preparation of bcx7353, expanding global commercial and manufacturing efforts​.BioCryst Pharmaceuticals Inc - proceeds to be used to support initiation of phase 3 clinical trial for bcx7353, long term safety study.​.  Full Article